Literature DB >> 30613303

Deficiency of TLR4 ameliorates hypoperfusion-induced brain pathology.

Yang Liu1,2,3, Klaus Fassbender1,2.   

Abstract

Microglial inflammatory activation contributes to chronic cerebral hypoperfusion-induced brain pathology. This editorial highlights a study by Qin et al. (Theranostics 2018; 8(19):5434-5451. doi:10.7150/thno.27882) that deficiency of TLR4 attenuates cognitive dysfunction and white matter injury by reducing autophagy and pro-inflammatory activation in microglia.

Entities:  

Keywords:  TLR4.; autophagy; chronic cerebral hypoperfusion; inflammation; microglia

Mesh:

Substances:

Year:  2018        PMID: 30613303      PMCID: PMC6299697          DOI: 10.7150/thno.30953

Source DB:  PubMed          Journal:  Theranostics        ISSN: 1838-7640            Impact factor:   11.556


Chronic cerebral hypoperfusion resulting from cerebral angiopathy or cardiac dysfunction is often associated with neurodegenerative diseases, especially Alzheimer's disease (AD) and subcortical ischemic vascular dementia 1, 2. One prospective study based on a large population recently showed that cerebral hypoperfusion occurs in pre-symptomatic AD patients and predicts the future development of AD 3. The chronically hypoperfused brain is pathologically characterized by white matter injury with demyelination and neuronal degeneration 2. Chronic cerebral hypoperfusion in mice can be induced by installing microcoils around the common carotid arteries on both sides of the animal, creating bilateral common carotid artery stenosis (BCAS) 4. Studies of the effects of chronic cerebral hypoperfusion using the BCAS animal model have shown that microglia are highly activated 4, 5. In a recent study, inhibition of microglial inflammatory activation reduced white matter lesions and improved cognitive deficits in BCAS mice 6, suggesting that microglia-dominated neurotoxic inflammatory activation might be one of the pathogenic mechanisms. However, the mechanism by which microglial activation is initiated and regulated in the hypoperfused brain remains unclear. In the recently published study 7, Dr. Wei Wang and colleagues established a BCAS model in wild-type C57BL/6J mice and CB57/10Scnj mice, which carry a spontaneous deletion of the gene encoding Toll-like receptor 4 (TLR4). They observed that deficiency of TLR4 significantly attenuates white matter lesions and improves cognitive function in BCAS mice. Interestingly, TLR4 deficiency shifts microglial activation from a pro-inflammatory to an anti-inflammatory profile in association with a decrease of autophagic activity in microglia. The authors further inhibited and activated autophagy in LPS- or interleukin 4 - treated cultured microglia with bafilomycin (or wortmannin) and rapamycin, respectively. They showed that activation of autophagy facilitates pro-inflammatory activation, while inhibition of autophagy displays contrary effects. Thus, they suggested that TLR4 deficiency induces anti-inflammatory polarization by inhibiting autophagy in microglia. The findings are interesting. However, further studies are necessary in order to clarify a few important issues on the pathogenic role of TLR4 in chronically hypoperfused brain: No causal link has yet been demonstrated between autophagic activation and TLR4-mediated inflammatory polarization in microglia. To test whether autophagy mediates TLR4 to regulate microglial inflammatory activation, autophagic activity in TLR4-deficient and wild-type microglia needs to be kept constant during inflammatory activation. Thus, some signaling molecules essential for autophagy, such as ATG5 or ATG7, can be deleted. When techniques to build genetic mouse or cell models are not available, microglia should be at least treated with autophagic inhibitors or enhancers. Oxygen-glucose deprivation (OGD), rather than lipopolysaccharide (LPS), should be used to activate cultured microglia 8. LPS-activated microglia do not model activated microglia in the hypoperfused brain. In this study, a BCAS model was established in mice completely deficient in TLR4. The protective effects of TLR4 deficiency observed in this study might be attributed to its deficiency in microglia, but also to its deficiency in other cells, given that TLR4 may also be expressed on neurons 9, astrocytes 10 and endothelial cells 11. The protective effect of TLR4-deficient microglia on chronic hypoperfusion-induced brain pathology needs to be investigated in a mouse model with a TLR4 deletion specifically in microglia; alternatively, TLR4-deficient bone marrow chimera mice might be used to create BCAS models 12. Chronic cerebral hypoperfusion is manifested in a wide variety of neurodegenerative and cerebral vascular diseases with a common feature of cognitive impairment. The underlying pathophysiology is not well understood and needs further investigation. Dr. Wang's study demonstrates that TLR4 contributes to chronic cerebral hypoperfusion-induced pro-inflammation and subsequent demyelination and neurodegeneration. This study sheds light on the understanding of pathogenic mechanisms and may offer a novel therapeutic target for patients with dementia.
  12 in total

1.  TRPM2 Channel Aggravates CNS Inflammation and Cognitive Impairment via Activation of Microglia in Chronic Cerebral Hypoperfusion.

Authors:  Jun Miyanohara; Masashi Kakae; Kazuki Nagayasu; Takayuki Nakagawa; Yasuo Mori; Ken Arai; Hisashi Shirakawa; Shuji Kaneko
Journal:  J Neurosci       Date:  2018-03-09       Impact factor: 6.167

2.  Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology.

Authors:  Wenlin Hao; Yang Liu; Shirong Liu; Silke Walter; Marcus O Grimm; Amanda J Kiliaan; Botond Penke; Tobias Hartmann; Claudia E Rübe; Michael D Menger; Klaus Fassbender
Journal:  Brain       Date:  2010-11-28       Impact factor: 13.501

3.  Cerebral Perfusion and the Risk of Dementia: A Population-Based Study.

Authors:  Frank J Wolters; Hazel I Zonneveld; Albert Hofman; Aad van der Lugt; Peter J Koudstaal; Meike W Vernooij; M Arfan Ikram
Journal:  Circulation       Date:  2017-06-06       Impact factor: 29.690

Review 4.  Subcortical ischaemic vascular dementia.

Authors:  Gustavo C Román; Timo Erkinjuntti; Anders Wallin; Leonardo Pantoni; Helena C Chui
Journal:  Lancet Neurol       Date:  2002-11       Impact factor: 44.182

5.  White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion.

Authors:  Masunari Shibata; Ryo Ohtani; Masafumi Ihara; Hidekazu Tomimoto
Journal:  Stroke       Date:  2004-10-07       Impact factor: 7.914

Review 6.  Cerebrovascular disease in ageing and Alzheimer's disease.

Authors:  Seth Love; J Scott Miners
Journal:  Acta Neuropathol       Date:  2015-12-28       Impact factor: 17.088

7.  Endothelial TLR4 and the microbiome drive cerebral cavernous malformations.

Authors:  Alan T Tang; Jaesung P Choi; Jonathan J Kotzin; Yiqing Yang; Courtney C Hong; Nicholas Hobson; Romuald Girard; Hussein A Zeineddine; Rhonda Lightle; Thomas Moore; Ying Cao; Robert Shenkar; Mei Chen; Patricia Mericko; Jisheng Yang; Li Li; Ceylan Tanes; Dmytro Kobuley; Urmo Võsa; Kevin J Whitehead; Dean Y Li; Lude Franke; Blaine Hart; Markus Schwaninger; Jorge Henao-Mejia; Leslie Morrison; Helen Kim; Issam A Awad; Xiangjian Zheng; Mark L Kahn
Journal:  Nature       Date:  2017-05-10       Impact factor: 49.962

8.  Dimethyl fumarate improves white matter function following severe hypoperfusion: Involvement of microglia/macrophages and inflammatory mediators.

Authors:  Jill H Fowler; Jamie McQueen; Philip R Holland; Yasmina Manso; Martina Marangoni; Fiona Scott; Emma Chisholm; Robert H Scannevin; Giles E Hardingham; Karen Horsburgh
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-13       Impact factor: 6.200

9.  Microglial TLR4-dependent autophagy induces ischemic white matter damage via STAT1/6 pathway.

Authors:  Chuan Qin; Qian Liu; Zi-Wei Hu; Luo-Qi Zhou; Ke Shang; Dale B Bosco; Long-Jun Wu; Dai-Shi Tian; Wei Wang
Journal:  Theranostics       Date:  2018-10-29       Impact factor: 11.556

10.  The novel estrogenic receptor GPR30 alleviates ischemic injury by inhibiting TLR4-mediated microglial inflammation.

Authors:  Zengli Zhang; Pei Qin; Youliang Deng; Zhi Ma; Hang Guo; Haiyun Guo; Yushu Hou; Shiquan Wang; Wangyuan Zou; Yanyuan Sun; Yulong Ma; Wugang Hou
Journal:  J Neuroinflammation       Date:  2018-07-12       Impact factor: 8.322

View more
  5 in total

1.  Andrographolide enhances hippocampal BDNF signaling and suppresses neuronal apoptosis, astroglial activation, neuroinflammation, and spatial memory deficits in a rat model of chronic cerebral hypoperfusion.

Authors:  Da-Peng Wang; Hang Yin; Qi Lin; Shu-Ping Fang; Jian-Hua Shen; Yi-Fang Wu; Shao-Hua Su; Jian Hai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-06-11       Impact factor: 3.000

Review 2.  Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.

Authors:  Vamsi Reddy; Dayton Grogan; Meenakshi Ahluwalia; Évila Lopes Salles; Pankaj Ahluwalia; Hesam Khodadadi; Katelyn Alverson; Andy Nguyen; Srikrishnan P Raju; Pankaj Gaur; Molly Braun; Fernando L Vale; Vincenzo Costigliola; Krishnan Dhandapani; Babak Baban; Kumar Vaibhav
Journal:  EPMA J       Date:  2020-04-15       Impact factor: 6.543

3.  TAK‑242 exerts a neuroprotective effect via suppression of the TLR4/MyD88/TRIF/NF‑κB signaling pathway in a neonatal hypoxic‑ischemic encephalopathy rat model.

Authors:  Lijun Jiang; Zhenxing Xu; Hui Li; Mingfu Wu; Fudong Wang; Shunying Liu; Jianlan Tao; Xing Feng
Journal:  Mol Med Rep       Date:  2020-06-11       Impact factor: 2.952

4.  Early Toll-like receptor 4 inhibition improves immune dysfunction in the hippocampus after hypoxic-ischemic brain damage.

Authors:  Zhu Xing; Tang Zhen; Fan Jie; Yu Jie; Liu Shiqi; Zhu Kaiyi; OuYang Zhicui; Hei Mingyan
Journal:  Int J Med Sci       Date:  2022-01-01       Impact factor: 3.738

5.  Resatorvid protects against hypoxic-ischemic brain damage in neonatal rats.

Authors:  Li-Jun Jiang; Zhen-Xing Xu; Ming-Fu Wu; Gai-Qin Dong; Li-Li Zhang; Jun-Yan Gao; Chen-Xi Feng; Xing Feng
Journal:  Neural Regen Res       Date:  2020-07       Impact factor: 5.135

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.